ELF3 and cancer: With the approval of several drugs (e.g., sorafenib, sulfasalazine, and artesunate) by the U.S. Food and Drug Administration (FDA) for treating different cancer types by inducing ferroptosis, the reactivation of ferroptosis could potentially revolutionize the treatment of human lung tumors with ELF3 overexpression and PTEN downregulation or loss-of-mutations.